These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 27551109)

  • 1. Chemotherapy for Triple-Negative Breast Cancer: Is More Better?
    Mayer EL; Burstein HJ
    J Clin Oncol; 2016 Oct; 34(28):3369-71. PubMed ID: 27551109
    [No Abstract]   [Full Text] [Related]  

  • 2. Adjuvant Capecitabine In Triple Negative Breast Cancer: The Earlier, The Better?
    Guven DC; Taban H; Dizdar O
    J Oncol Pharm Pract; 2022 Jan; 28(1):203-204. PubMed ID: 34628993
    [No Abstract]   [Full Text] [Related]  

  • 3. Mise en place: toward neoadjuvant chemoimmunotherapy for early triple-negative breast cancer.
    van Dongen MGJ; Kok M
    Ann Oncol; 2020 May; 31(5):556-557. PubMed ID: 32171753
    [No Abstract]   [Full Text] [Related]  

  • 4. [Not Available].
    Gonçalves A
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S76-89. PubMed ID: 27494978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Critical Appraisal of Adjuvant Platinum-Based Chemotherapy for Basal Subtype Triple-Negative Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy.
    Shimoi T; Noguchi E; Sudo K; Chua YJ; Yonemori K
    J Clin Oncol; 2021 Nov; 39(31):3519-3521. PubMed ID: 34554822
    [No Abstract]   [Full Text] [Related]  

  • 6. Features from Computerized Texture Analysis of Breast Cancers at Pretreatment MR Imaging Are Associated with Response to Neoadjuvant Chemotherapy.
    Chamming's F; Ueno Y; Ferré R; Kao E; Jannot AS; Chong J; Omeroglu A; Mesurolle B; Reinhold C; Gallix B
    Radiology; 2018 Feb; 286(2):412-420. PubMed ID: 28980886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
    Darb-Esfahani S; Denkert C; Stenzinger A; Salat C; Sinn B; Schem C; Endris V; Klare P; Schmitt W; Blohmer JU; Weichert W; Möbs M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Loi S; Untch M; von Minckwitz G; Nekljudova V; Loibl S
    Oncotarget; 2016 Oct; 7(42):67686-67698. PubMed ID: 27611952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple-Negative Breast Cancer: Who Should Receive Neoadjuvant Chemotherapy?
    Chaudhary LN; Wilkinson KH; Kong A
    Surg Oncol Clin N Am; 2018 Jan; 27(1):141-153. PubMed ID: 29132557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation Recall Dermatitis After Capecitabine in a Patient With Triple Negative Breast Cancer.
    Laird J; Leventhal J; Kanowitz J; Damast S
    Pract Radiat Oncol; 2021; 11(6):448-452. PubMed ID: 34157449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New drug approval: Pembrolizumab - Neoadjuvant/adjuvant treatment for localized high-risk triple negative breast cancer].
    Minot-This MS; Deleuze A
    Bull Cancer; 2022 Oct; 109(10):988-989. PubMed ID: 35871860
    [No Abstract]   [Full Text] [Related]  

  • 11. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer.
    Koolen BB; Pengel KE; Wesseling J; Vogel WV; Vrancken Peeters MJ; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
    Breast; 2013 Oct; 22(5):691-7. PubMed ID: 23414930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer.
    Nabholtz JM; Chalabi N; Radosevic-Robin N; Dauplat MM; Mouret-Reynier MA; Van Praagh I; Servent V; Jacquin JP; Benmammar KE; Kullab S; Bahadoor MR; Kwiatkowski F; Cayre A; Abrial C; Durando X; Bignon YJ; Chollet P; Penault-Llorca F
    Int J Cancer; 2016 May; 138(9):2274-80. PubMed ID: 26649807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant treatment of breast cancer--Clinical and research perspective.
    Loibl S; Denkert C; von Minckwitz G
    Breast; 2015 Nov; 24 Suppl 2():S73-7. PubMed ID: 26387601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnetic resonance examination to predict pathological complete response following neoadjuvant chemotherapy: when is it appropriate for HER2-positive and triple-negative breast cancers?
    Okamoto S; Yamada T; Kanemaki Y; Kojima Y; Tsugawa K; Nakajima Y
    Breast Cancer; 2016 Sep; 23(5):789-96. PubMed ID: 26437647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
    Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncologic safety of breast-conserving surgery compared to mastectomy in patients receiving neoadjuvant chemotherapy for locally advanced breast cancer.
    Cho JH; Park JM; Park HS; Park S; Kim SI; Park BW
    J Surg Oncol; 2013 Dec; 108(8):531-6. PubMed ID: 24115142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors.
    Li F; Ma L; Geng C; Liu C; Deng H; Yue M; Ding Y; Wang X; Liu Y
    Pathol Res Pract; 2018 Aug; 214(8):1166-1172. PubMed ID: 29945816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GATA-3 expression is not associated with complete pathological response in triple negative breast cancer patients treated with neoadjuvant chemotherapy.
    Wasserman JK; Williams PA; Islam S; Robertson SJ
    Pathol Res Pract; 2016 Jun; 212(6):539-44. PubMed ID: 27067807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.
    Steenbruggen TG; van Ramshorst MS; Kok M; Linn SC; Smorenburg CH; Sonke GS
    Drugs; 2017 Aug; 77(12):1313-1336. PubMed ID: 28616845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.